Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers

NCT05792917 | Completed Phase 1

• 1 other identifier: CIBI306K101
• Study Type: interventional
• Target: 166
• Locations: 1 country
• Sites: 1

Brief Summary

This trial is conducted in China. The purpose of this study is to evaluate the pharmacokinetic similarity of Tafolecimab with different manufacturing process in healthy male subjects. Another purpose is to determine safety, and immunogenicity of sintilimab with different manufacturing process,also to determine Pharmacodynamics of Tafolecimab with different manufacturing process

Conditions

Healthy Male Subjects

Outcome Measures

Primary Outcomes (2)

• Bioequivalence results using the peak serum drug concentration (Cmax) as the judging indicators

  up to Day 57

• Bioequivalence results using the area under the serum concentration-time curve (AUC0-inf) as the judging indicators

  up to Day 57

Secondary Outcomes (8)

• Other PK parameters: Area under the plasma concentration-time curve (AUClast)

  up to Day 57

• Other PK parameters: Volume of distribution (V)

  up to Day 57

• Other PK parameters: elimination half-life (t1/2)

  up to Day 57

• Number of participants with adverse events, with abnormal vital signs, abnormal physical examination, abnormal laboratory test results and abnormal ECG readings

  up to Day 57

• The occurrence of Anti-drug Antibody(ADA)

  up to Day 57

Study Arms (2)

tafolecimab (a modified manufacturing process)

EXPERIMENTAL

450mg，SC，single dose

Drug: tafolecimab (a modified manufacturing process)

tafolecimab (a original manufacturing process)

ACTIVE COMPARATOR

450mg，SC，single dose

Drug: tafolecimab (a original manufacturing process)

Interventions

tafolecimab (a modified manufacturing process) DRUG

450mg，SC，single dose

Also known as: IBI306 (a modified manufacturing process)

tafolecimab (a modified manufacturing process)

tafolecimab (a original manufacturing process) DRUG

450mg，SC，single dose

Also known as: IBI306 (a original manufacturing process)

tafolecimab (a original manufacturing process)

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male subjects between 18 and 65 years of age, inclusive.
• Low-density lipoprotein cholesterol (LDL-C) within the range of 1.8 mmol/L to 4.9 mmol/L, inclusive, at screening.
• Body weight within the range of 63.0 kilograms (kg) to 75.0 kg, inclusive.
• Subjects who are willing maintain current normal diet and physical activity.
• Subjects agree to use reliable contraceptive measures (such as abstinence, sterilization, contraceptives, injectable contraceptive medroxyprogesterone or subcutaneous implant contraception, etc.) during the study period and within 6 months after the study drug infusion.
• No history of serious diseases, including (but not limited to) cardiovascular, hepatic, renal, gastrointestinal, psychiatric, neurologic, endocrine, pulmonary, hematological, immune disease.
• Subjects voluntarily signed the informed consent form and agreed to strictly follow the requirements of this protocol.

You may not qualify if:

• Subjects who have a history of allergy, or may be allergic to the investigational drug and the related compounds.
• Have used the inhibitors of proprotein convertase subtilisin type 9 (PCSK-9).
• Have clinically relevant abnormalities identified by Vital signs, physical examination, clinical laboratory tests, 12-lead ECG, or chest X-ray, at screening.
• Unwilling to stop any strenuous physical activity (such as weightlifting or long-distance running) within 72 hours before the planned follow-up visit.
• History of hospitalization within 1 month before screening, major surgery within 6 months before screening, or other unstable conditions judged by the investigator.
• The last dose of the previous investigational product which is chemical drug has been given in less than 1 month before administration.
• The last dose of the previous investigational product which is biological drug has been given in less than 3 months before administration.
• Have used any drugs (including over-the-counter drugs or prescription drugs), the last medication is less than 14 days or the last medication is less than 5 half-lives of the drug from the administration day (whichever is longer), or are using any drugs.
• Have used any traditional Chinese medicines, vitamins or drugs or supplements known to affect lipid metabolism within 30 days before administration.
• Have a positive test result of human immunodeficiency virus (Human Immunodeficiency Virus, HIV) antibody, hepatitis B virus surface antigen (HBsAg), Hepatitis C virus (HCV) antibody or syphilis test at screening.
• History of alcohol or drug abuse results within 12 months before screening. Average daily alcohol intake is more than 3 units of alcohol (male) (1 unit≈360mL beer, or 45mL spirits with 40% alcohol content, or 150mL wine), or unwilling to stop drinking 72 hours before administration and throughout the study period, or a positive ethanol breath test at screening, or positive drug screening results by urine at screening.
• unable to abstain from smoking, alcohol and caffeinated beverages within 72 hours before administration and throughout the study period.
• lost blood, donated blood ≥200 ml within 2 months before screening.
• History of organ transplantation or malignant tumor.
• Not suitable for this study in the investigator's opinion.

Sponsors & Collaborators

• Innovent Biologics (Suzhou) Co. Ltd.: lead

Study Sites (1)

Aerospace Center Hospital

Beijing, China

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 6, 2023
• First Posted: March 31, 2023
• Study Start: March 6, 2023
• Primary Completion: March 26, 2023
• Study Completion: August 4, 2023
• Last Updated: September 13, 2023

Record last verified: 2023-04

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)